{"id":"d396baa9c1f2","type":"article","url":"https://hartvaat.nl/2020/11/10/chinese-kruidenformule-voor-gemaskeerde-hypertensie-gerandomiseerde-placebogecon/","title":"Chinese kruidenformule voor gemaskeerde hypertensie: gerandomiseerde placebogecontroleerde trial","title_en":"Treatment of Masked Hypertension with a Chinese Herbal Formula: A Randomized, Placebo-Controlled Trial.","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","huisarts"],"tags":["bloeddrukbehandeling"],"journal":"Circulation","doi":"10.1161/CIRCULATIONAHA.120.046685","source_url":"https://doi.org/10.1161/CIRCULATIONAHA.120.046685","authors":["Dong-Yan Zhang","Yi-Bang Cheng","Qian-Hui Guo","Xiao-Li Shan","Fang-Fei Wei","Feng Lu","Chang-Sheng Sheng","Qi-Fang Huang","Chuan-Hua Yang","Yan Li","Ji-Guang Wang"],"significance":5,"published":"2020-11-10","source_date":"2020-11-10","image":"","kennis":[],"congress":"","summary_en":"This randomized placebo-controlled trial tested a Chinese herbal formula for treating masked hypertension, providing the first controlled evidence for traditional herbal medicine in this specific blood pressure phenotype.","created":"2026-07-03T10:28:53Z","updated":"2026-07-03T18:38:48Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.","body_markdown":"Gerandomiseerde placebogecontroleerde trial naar een Chinese kruidenformule voor behandeling van gemaskeerde hypertensie.","abstract_original":"BACKGROUND: Masked hypertension is associated with adverse cardiovascular outcomes. Nonetheless, no randomized controlled trials exist in the treatment of masked hypertension. The aim of this randomized, placebo-controlled trial was to investigate the efficacy and safety of blood pressure (BP)-lowering treatment with a Chinese herbal formula, gastrodia-uncaria granules, in patients with masked hypertension. METHODS: Patients with an office BP of <140/90 mm Hg and daytime ambulatory BP of 135 to 150 mm Hg systolic or 85 to 95 mm Hg diastolic were randomly assigned 1:1 to the treatment of gastrodia-uncaria granules or placebo 5 to 10 g twice daily for 4 weeks. The primary efficacy variable was the change in daytime ambulatory BP. RESULTS: At baseline, office and daytime BP of the 251 participants (mean age, 50.4 years; 53.4% men; mean body mass index 24.5 kg/m2; and 2.8%, 1.6%, and 30.7% with cardiovascular disease, diabetes, and smoking, respectively) averaged 129/82 and 135/89 mm Hg, respectively. In the intention-to-treat analysis, daytime systolic/diastolic BP was reduced by 5.44/3.39 and 2.91/1.60 mm Hg in the gastrodia-uncaria granules and placebo groups, respectively. The between-group difference in BP reductions was significant for the daytime (2.52/1.79 mm Hg; P≤0.025) and 24-hour BP (2.33/1.49 mm Hg; P≤0.012), but not for the clinic and nighttime BPs (P≥0.162). The per-protocol analysis in 229 patients produced similar results. Only 1 adverse event (sleepiness during the day) was reported, and no serious adverse event occurred. CONCLUSIONS: BP-lowering treatment with Chinese traditional medicine gastrodia-uncaria granules is efficacious for patients with masked hypertension. Registration: URL: https://www.clinicaltrials.gov; Unique identifier: NCT02156024."}